Cerebroprotection as an adjunct to mechanical thrombectomy

Dr. Staszewski presented results of the CERECAP (CErebrolysin RECanalization And Perfusion) WIM (Wojskowy Instytut Medyczny) study, highlighting the gap between trial results of endovascular thrombectomy and less favorable real-world outcomes, where many patients remain disabled despite successful recanalization. (Figure 6) He argued that thrombectomy provides ideal conditions for cerebroprotection and that Cerebrolysin, with multimodal protective effects, could enhance recovery.

In his single-center prospective study, 50 thrombectomy patients received Cerebrolysin in two cycles and were compared with 50 historical controls. At three months, functional independence was achieved in 68% of the Cerebrolysin group versus 44% of controls, with better early recovery, higher discharge to home rates and fewer long-term care needs. At 12 months, independence increased even further to  75% versus 46%, with notable benefits in diabetic patients.

The study concluded that Cerebrolysin is a safe and effective adjunct to thrombectomy, improving functional outcomes and reducing complications.